| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 15 | 2023 | 543 | 4.220 |
Why?
|
| Mycobacterium tuberculosis | 7 | 2018 | 329 | 2.020 |
Why?
|
| Hemorrhagic Fever, Ebola | 6 | 2015 | 9 | 1.740 |
Why?
|
| Anti-Bacterial Agents | 8 | 2021 | 293 | 1.690 |
Why?
|
| HIV Infections | 18 | 2024 | 5097 | 1.660 |
Why?
|
| HIV Seropositivity | 4 | 2022 | 265 | 1.540 |
Why?
|
| Humans | 52 | 2024 | 14537 | 1.470 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2015 | 35 | 1.320 |
Why?
|
| Delivery of Health Care | 4 | 2021 | 239 | 1.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 1.190 |
Why?
|
| Health Personnel | 3 | 2020 | 231 | 1.170 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 104 | 1.170 |
Why?
|
| Primary Health Care | 3 | 2020 | 240 | 1.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 43 | 1.070 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 7 | 1.020 |
Why?
|
| Tuberculosis, Meningeal | 2 | 2018 | 10 | 1.010 |
Why?
|
| Sputum | 3 | 2018 | 135 | 1.010 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 37 | 0.950 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2023 | 324 | 0.940 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 112 | 0.930 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2019 | 195 | 0.920 |
Why?
|
| Practice Guidelines as Topic | 3 | 2023 | 127 | 0.890 |
Why?
|
| Clinical Decision-Making | 3 | 2023 | 18 | 0.860 |
Why?
|
| Disease Outbreaks | 3 | 2020 | 111 | 0.840 |
Why?
|
| Tuberculin Test | 2 | 2015 | 49 | 0.840 |
Why?
|
| Respiratory Tract Infections | 3 | 2016 | 266 | 0.810 |
Why?
|
| Adult | 20 | 2024 | 5913 | 0.780 |
Why?
|
| Antitubercular Agents | 4 | 2023 | 322 | 0.780 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2019 | 4 | 0.740 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2023 | 226 | 0.730 |
Why?
|
| Female | 23 | 2024 | 9103 | 0.730 |
Why?
|
| Bacteremia | 3 | 2018 | 79 | 0.730 |
Why?
|
| Male | 20 | 2024 | 6754 | 0.690 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2017 | 47 | 0.680 |
Why?
|
| South Africa | 17 | 2023 | 7596 | 0.660 |
Why?
|
| Health Facilities | 1 | 2020 | 40 | 0.650 |
Why?
|
| Cerebrospinal Fluid | 2 | 2017 | 5 | 0.640 |
Why?
|
| Infectious Disease Medicine | 1 | 2019 | 1 | 0.620 |
Why?
|
| Specialization | 1 | 2019 | 8 | 0.620 |
Why?
|
| Penicillanic Acid | 2 | 2018 | 4 | 0.620 |
Why?
|
| Treatment Outcome | 5 | 2024 | 889 | 0.620 |
Why?
|
| Pneumocystis carinii | 2 | 2024 | 9 | 0.620 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2024 | 16 | 0.610 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2018 | 135 | 0.600 |
Why?
|
| Communicable Diseases | 1 | 2019 | 62 | 0.590 |
Why?
|
| Mass Screening | 3 | 2022 | 245 | 0.550 |
Why?
|
| Infection Control | 2 | 2020 | 31 | 0.530 |
Why?
|
| Bacterial Infections | 2 | 2017 | 54 | 0.530 |
Why?
|
| Rifampin | 2 | 2017 | 197 | 0.530 |
Why?
|
| Intracranial Hypertension | 1 | 2017 | 1 | 0.530 |
Why?
|
| Anti-Retroviral Agents | 2 | 2012 | 551 | 0.530 |
Why?
|
| Spinal Puncture | 1 | 2017 | 4 | 0.530 |
Why?
|
| Chemical Phenomena | 1 | 2017 | 6 | 0.530 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 3 | 0.520 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2017 | 16 | 0.520 |
Why?
|
| Patient Isolation | 2 | 2015 | 5 | 0.510 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 54 | 0.500 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 56 | 0.490 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 262 | 0.490 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2015 | 3 | 0.480 |
Why?
|
| Fungemia | 1 | 2015 | 2 | 0.480 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2015 | 1 | 0.480 |
Why?
|
| Cephalosporins | 1 | 2015 | 4 | 0.480 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2015 | 3 | 0.480 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2015 | 7 | 0.470 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 12 | 0.470 |
Why?
|
| Levofloxacin | 1 | 2015 | 21 | 0.470 |
Why?
|
| Blood | 1 | 2015 | 51 | 0.460 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 38 | 0.460 |
Why?
|
| Pyrazines | 1 | 2015 | 1 | 0.450 |
Why?
|
| Health Resources | 1 | 2015 | 66 | 0.450 |
Why?
|
| Sensitivity and Specificity | 6 | 2023 | 385 | 0.450 |
Why?
|
| Amides | 1 | 2015 | 8 | 0.450 |
Why?
|
| Prospective Studies | 7 | 2023 | 1160 | 0.440 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 102 | 0.430 |
Why?
|
| Diet, Fat-Restricted | 1 | 2013 | 1 | 0.420 |
Why?
|
| Drug Utilization | 1 | 2013 | 10 | 0.420 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 132 | 0.410 |
Why?
|
| Middle Aged | 10 | 2024 | 3601 | 0.410 |
Why?
|
| Women's Health | 1 | 2013 | 41 | 0.410 |
Why?
|
| beta-Glucans | 1 | 2013 | 1 | 0.410 |
Why?
|
| Feeding Behavior | 1 | 2013 | 60 | 0.400 |
Why?
|
| Predictive Value of Tests | 5 | 2016 | 188 | 0.390 |
Why?
|
| Diarrhea | 2 | 2015 | 76 | 0.390 |
Why?
|
| Isosporiasis | 1 | 2012 | 1 | 0.380 |
Why?
|
| Disease Eradication | 1 | 2012 | 11 | 0.380 |
Why?
|
| Isoniazid | 1 | 2012 | 110 | 0.350 |
Why?
|
| School Health Services | 1 | 2011 | 19 | 0.340 |
Why?
|
| Health Education | 1 | 2011 | 35 | 0.340 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2010 | 1 | 0.340 |
Why?
|
| AIDS Serodiagnosis | 1 | 2011 | 44 | 0.340 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 237 | 0.330 |
Why?
|
| Emergency Medical Services | 1 | 2010 | 29 | 0.330 |
Why?
|
| Patient Compliance | 1 | 2011 | 120 | 0.330 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 16 | 0.330 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 101 | 0.330 |
Why?
|
| Rural Health | 1 | 2010 | 118 | 0.320 |
Why?
|
| Betacoronavirus | 2 | 2020 | 52 | 0.320 |
Why?
|
| Hepatitis B | 1 | 2011 | 125 | 0.310 |
Why?
|
| HIV-1 | 2 | 2019 | 1260 | 0.290 |
Why?
|
| Developing Countries | 1 | 2011 | 400 | 0.290 |
Why?
|
| Pandemics | 2 | 2020 | 296 | 0.280 |
Why?
|
| Fatty Liver | 1 | 2007 | 8 | 0.270 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 26 | 0.260 |
Why?
|
| Consensus | 3 | 2023 | 62 | 0.260 |
Why?
|
| Hospitals | 2 | 2020 | 103 | 0.260 |
Why?
|
| Morpholines | 1 | 2024 | 5 | 0.230 |
Why?
|
| Hypoxia | 1 | 2024 | 12 | 0.220 |
Why?
|
| Pyridines | 1 | 2024 | 11 | 0.220 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 217 | 0.220 |
Why?
|
| Oxazines | 1 | 2024 | 81 | 0.210 |
Why?
|
| Endocarditis | 1 | 2023 | 4 | 0.200 |
Why?
|
| Endocarditis, Bacterial | 1 | 2023 | 7 | 0.200 |
Why?
|
| Mortality | 3 | 2021 | 104 | 0.190 |
Why?
|
| beta-Lactamases | 1 | 2021 | 23 | 0.180 |
Why?
|
| Sierra Leone | 3 | 2015 | 11 | 0.180 |
Why?
|
| Coinfection | 1 | 2023 | 276 | 0.170 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 7 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2023 | 55 | 0.170 |
Why?
|
| Algorithms | 2 | 2018 | 106 | 0.170 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 2 | 0.170 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 32 | 0.170 |
Why?
|
| Environment Design | 1 | 2020 | 3 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2015 | 967 | 0.170 |
Why?
|
| Hand Disinfection | 1 | 2020 | 9 | 0.170 |
Why?
|
| Disinfection | 1 | 2020 | 6 | 0.170 |
Why?
|
| Mobile Health Units | 1 | 2020 | 7 | 0.170 |
Why?
|
| Prognosis | 2 | 2023 | 199 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 11 | 0.160 |
Why?
|
| Capacity Building | 1 | 2020 | 32 | 0.160 |
Why?
|
| Coronavirus | 1 | 2020 | 14 | 0.160 |
Why?
|
| Decision Making | 1 | 2020 | 53 | 0.160 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 1 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 125 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 74 | 0.160 |
Why?
|
| Mycoses | 1 | 2019 | 8 | 0.160 |
Why?
|
| Escherichia coli Infections | 1 | 2018 | 3 | 0.150 |
Why?
|
| Thienamycins | 1 | 2018 | 6 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2018 | 30 | 0.140 |
Why?
|
| Ebolavirus | 2 | 2015 | 4 | 0.140 |
Why?
|
| Klebsiella Infections | 1 | 2018 | 13 | 0.140 |
Why?
|
| Klebsiella pneumoniae | 1 | 2018 | 39 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 77 | 0.140 |
Why?
|
| Private Sector | 1 | 2018 | 45 | 0.140 |
Why?
|
| Epidemics | 2 | 2015 | 65 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 31 | 0.140 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 187 | 0.140 |
Why?
|
| Public Sector | 1 | 2018 | 82 | 0.140 |
Why?
|
| Logistic Models | 1 | 2018 | 254 | 0.140 |
Why?
|
| Time Factors | 2 | 2016 | 507 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2017 | 81 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2017 | 6 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 21 | 0.130 |
Why?
|
| Drug Costs | 1 | 2017 | 18 | 0.130 |
Why?
|
| Hospitals, Public | 1 | 2017 | 45 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 90 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 472 | 0.130 |
Why?
|
| Probability | 1 | 2016 | 27 | 0.120 |
Why?
|
| Bacterial Translocation | 1 | 2015 | 2 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2015 | 34 | 0.120 |
Why?
|
| Georgia | 1 | 2015 | 4 | 0.120 |
Why?
|
| Aged | 4 | 2024 | 1740 | 0.120 |
Why?
|
| Africa, Western | 1 | 2015 | 8 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2015 | 16 | 0.120 |
Why?
|
| Viral Load | 1 | 2019 | 819 | 0.120 |
Why?
|
| HIV | 1 | 2018 | 380 | 0.120 |
Why?
|
| Hematologic Tests | 1 | 2015 | 11 | 0.110 |
Why?
|
| World Health Organization | 1 | 2015 | 137 | 0.110 |
Why?
|
| False Positive Reactions | 1 | 2014 | 17 | 0.110 |
Why?
|
| Sepsis | 1 | 2015 | 102 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 91 | 0.110 |
Why?
|
| Public Health | 1 | 2015 | 124 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2019 | 656 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2015 | 105 | 0.110 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 1324 | 0.110 |
Why?
|
| Lung | 1 | 2014 | 70 | 0.110 |
Why?
|
| Inpatients | 1 | 2013 | 30 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1422 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 146 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 63 | 0.100 |
Why?
|
| Isospora | 1 | 2012 | 1 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 21 | 0.100 |
Why?
|
| Risk | 1 | 2012 | 87 | 0.090 |
Why?
|
| Young Adult | 3 | 2015 | 2498 | 0.090 |
Why?
|
| Prevalence | 2 | 2015 | 1192 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2011 | 23 | 0.090 |
Why?
|
| Self-Help Groups | 1 | 2011 | 3 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 6 | 0.090 |
Why?
|
| Confidentiality | 1 | 2011 | 13 | 0.090 |
Why?
|
| Rural Population | 2 | 2015 | 654 | 0.090 |
Why?
|
| Rural Health Services | 1 | 2011 | 48 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 101 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 151 | 0.080 |
Why?
|
| Poverty | 1 | 2011 | 152 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2011 | 151 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2023 | 96 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 280 | 0.070 |
Why?
|
| Adolescent | 2 | 2015 | 2985 | 0.070 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2007 | 1 | 0.070 |
Why?
|
| Observer Variation | 1 | 2007 | 15 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 9 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2023 | 799 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 529 | 0.060 |
Why?
|
| Pregnancy | 1 | 2011 | 1862 | 0.060 |
Why?
|
| Child | 1 | 2011 | 2242 | 0.060 |
Why?
|
| Pyridazines | 1 | 2024 | 6 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 11 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2024 | 32 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2024 | 272 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2024 | 19 | 0.050 |
Why?
|
| Viremia | 1 | 2023 | 66 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 38 | 0.050 |
Why?
|
| Hospitalization | 1 | 2024 | 418 | 0.050 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 33 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 17 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 30 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 198 | 0.040 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 156 | 0.040 |
Why?
|
| Darunavir | 1 | 2019 | 12 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 50 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 59 | 0.040 |
Why?
|
| Lopinavir | 1 | 2019 | 137 | 0.040 |
Why?
|
| Piperacillin | 1 | 2018 | 3 | 0.040 |
Why?
|
| Ritonavir | 1 | 2019 | 137 | 0.040 |
Why?
|
| Ceftriaxone | 1 | 2018 | 13 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2018 | 30 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2018 | 57 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2019 | 278 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 221 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 26 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2016 | 55 | 0.030 |
Why?
|
| Confusion | 1 | 2015 | 1 | 0.030 |
Why?
|
| Conjunctivitis, Viral | 1 | 2015 | 1 | 0.030 |
Why?
|
| Hiccup | 1 | 2015 | 1 | 0.030 |
Why?
|
| Nausea | 1 | 2015 | 2 | 0.030 |
Why?
|
| Vomiting | 1 | 2015 | 4 | 0.030 |
Why?
|
| Fever | 1 | 2015 | 26 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 20 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 149 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 40 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 327 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2015 | 303 | 0.030 |
Why?
|